KALVISTA PHARMACEUTICALS INC(NASDAQ:KALV) stock News

KALV Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

18 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

21 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Stocktwits - Mentions: VFMO VTWG

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

22 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

a month ago - By: Benzinga

KalVista Pharma's Earnings: A Preview

a month ago - By: Benzinga - Mentions: DYAI KPTI ICU SXTC ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

a month ago - By: The Motley Fool

KalVista Posts 154% Expense Jump in Q1

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

2 months ago - By: Metagenomi, Inc. - Mentions: MGX

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

4 months ago - By: Yahoo Finance - Mentions: VZ

KalVista price target raised to $37 from $22 at BofA

4 months ago - By: Stocktwits - Mentions: VFMO IWMW

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

4 months ago - By: Investor's Business Daily

KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment

4 months ago - By: Bloomberg

KalVista Shares Surge as FDA Approves New Drug After Delay

4 months ago - By: KalVista Pharmaceuticals, Inc.

KALVISTA PHARMACEUTICALS INC (KALV) Stock News

KALV Latest News, Press Relases and Analysis

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

KalVista Pharma's Earnings: A Preview

12 Health Care Stocks Moving In Wednesday's After-Market Session

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

KalVista Posts 154% Expense Jump in Q1

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

KalVista price target raised to $37 from $22 at BofA

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment

KalVista Shares Surge as FDA Approves New Drug After Delay

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema